DANA SMART: Open Payments
NPI 1639657273 · BRANFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,346 in 59 payments from 13 companies in 2025. Trend: 2023 $1,616 · 2024 $1,894 · 2025 $2,346
Food & beverage: $2,339Education: $7
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $622 |
| Otsuka America Pharmaceutical, Inc. | 14 | $427 |
| Janssen Pharmaceuticals, Inc | 2 | $298 |
| Neurocrine BioSciences, Inc. | 7 | $204 |
| Vanda Pharmaceuticals Inc. | 2 | $153 |
| Axsome Therapeutics, Inc. | 3 | $151 |
| Lundbeck LLC | 8 | $150 |
| Luye Pharma (USA) Ltd. | 1 | $123 |
| E.R. Squibb & Sons, L.L.C. | 3 | $86 |
| ABBVIE INC. | 3 | $58 |
Products named: CAPLYTA, REXULTI, INVEGA SUSTENNA, INGREZZA, FANAPT, Auvelity, ERZOFRI EXTENDED-RELEASE, COBENFY.
Industry payments across CT — which companies pay providers there.
